{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T14:52:05Z","timestamp":1780498325472,"version":"3.54.1"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T00:00:00Z","timestamp":1673913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Hypokalemic periodic paralysis (HPP) is a heterogeneous group of diseases characterized by intermittent episodes of delayed paralysis of skeletal muscle with episodes of hypokalemia, caused by variants in CACNA1S or SCN4A genes, or secondary to thyrotoxicosis, Sjogren syndrome, primary aldosteronism, etc. HPP may be the only presentation in Andersen\u2013Tawil syndrome in which the majority of cases are caused by pathogenic variants in the KCNJ2 gene. We present a case of a 29-year-old male with hypokalemic periodic paralysis. The patient began to experience recurrent weakness of the extremities at the age of 26, which was effectively treated with potassium supplementation. He had recently developed dry mouth, palpitations, weight loss, and even dyspnea, with a serum potassium level as low as 1.59 mmol\/L. The results of auxiliary examinations showed Graves' disease, and genetic testing indicated a missense variant, NM_000334.4 (SCN4A):c.3404G&amp;gt;A (p.R1135H). He did not experience periodic paralysis during follow-up after lifestyle guidance and treatment of thyrotoxicosis with radioactive iodine. It is a rare case of SCN4A p.R1135H gene variant combined with hyperthyroidism resulting in HPP with respiratory muscle paralysis to raise awareness of the disease and avoid misdiagnosis and missed diagnosis.<\/jats:p>","DOI":"10.3389\/fneur.2022.1078784","type":"journal-article","created":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T04:44:46Z","timestamp":1673930686000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Case report: SCN4A p.R1135H gene variant in combination with thyrotoxicosis causing hypokalemic periodic paralysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Zhi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Banghui","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1093\/brain\/awh639","article-title":"The primary periodic paralyses: diagnosis, pathogenesis and treatment","volume":"129","author":"Venance","year":"2006","journal-title":"Brain"},{"key":"B2","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1600-0404.2007.00963.x","article-title":"Primary periodic paralyses","volume":"117","author":"Finsterer","year":"2008","journal-title":"Acta Neurol Scand"},{"key":"B3","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1007\/s13311-018-00678-0","article-title":"Skeletal muscle channelopathies","volume":"15","author":"Phillips","year":"2018","journal-title":"Neurotherapeutics"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.3390\/cells10061521","article-title":"Ion channel gene mutations causing skeletal muscle disorders: pathomechanisms and opportunities for therapy","volume":"10","author":"Maggi","year":"2021","journal-title":"Cells"},{"key":"B5","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1681\/ASN.2012010046","article-title":"Mechanism of thyrotoxic periodic paralysis","volume":"23","author":"Lin","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1111\/j.1468-1331.2008.02132.x","article-title":"Hypokalemic thyrotoxic periodic paralysis: clinical characteristics and predictors of recurrent paralytic attacks","volume":"15","author":"Hsieh","year":"2008","journal-title":"Eur J Neurol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1210\/jc.2006-0356","article-title":"Clinical review: thyrotoxic periodic paralysis: a diagnostic challenge","volume":"91","author":"Kung","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1097\/MAJ.0b013e31822b430c","article-title":"Genotype and phenotype analysis of patients with sporadic periodic paralysis","volume":"343","author":"Sung","year":"2012","journal-title":"Am J Med Sci"},{"key":"B9","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.cell.2009.12.024","article-title":"Mutations in potassium channel Kir2.6 cause susceptibility to thyrotoxic hypokalemic periodic paralysis","volume":"140","author":"Ryan","year":"2010","journal-title":"Cell"},{"key":"B10","doi-asserted-by":"publisher","first-page":"27425","DOI":"10.1074\/jbc.M111.249656","article-title":"Identification and functional characterization of Kir2.6 mutations associated with non-familial hypokalemic periodic paralysis","volume":"286","author":"Cheng","year":"2011","journal-title":"J Biol Chem"},{"key":"B11","doi-asserted-by":"publisher","first-page":"6338","DOI":"10.1210\/jc.2019-00672","article-title":"Contribution of Asian haplotype of KCNJ18 to susceptibility to and ethnic differences in thyrotoxic periodic paralysis","volume":"104","author":"Noso","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B12","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0025-6196(11)62965-0","article-title":"Thyrotoxic periodic paralysis","volume":"80","author":"Lin","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1089\/thy.2008.0232","article-title":"Thyrotoxic periodic paralysis complicated by acute hypercapnic respiratory failure and ventricular tachycardia","volume":"18","author":"Wu","year":"2008","journal-title":"Thyroid"},{"key":"B14","doi-asserted-by":"publisher","first-page":"7093","DOI":"10.1021\/jm501981g","article-title":"Voltage-gated sodium channels: structure, function, pharmacology, and clinical indications","volume":"58","author":"de Lera Ruiz","year":"2015","journal-title":"J Med Chem"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1212\/WNL.53.9.1932","article-title":"A novel sodium channel mutation in a family with hypokalemic periodic paralysis","volume":"53","author":"Bulman","year":"1999","journal-title":"Neurology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1212\/01.wnl.0000342387.65477.46","article-title":"Voltage sensor charge loss accounts for most cases of hypokalemic periodic paralysis","volume":"72","author":"Matthews","year":"2009","journal-title":"Neurology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1093\/brain\/awu015","article-title":"NaV1.4 mutations cause hypokalaemic periodic paralysis by disrupting IIIS4 movement during recovery","volume":"137","author":"Groome","year":"2014","journal-title":"Brain"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1212\/WNL.0b013e31828cf8d0","article-title":"Prevalence study of genetically defined skeletal muscle channelopathies in England","volume":"80","author":"Horga","year":"2013","journal-title":"Neurology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"19604","DOI":"10.1212\/WNL.0b013e31823a0cb6","article-title":"Acetazolamide efficacy in hypokalemic periodic paralysis and the predictive role of genotype","volume":"77","author":"Matthews","year":"2011","journal-title":"Neurology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1093\/brain\/124.6.1091","article-title":"Hypokalaemic periodic paralysis type 2 caused by mutations at codon 672 in the muscle sodium channel gene SCN4A","volume":"124","author":"Sternberg","year":"2001","journal-title":"Brain"},{"key":"B21","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s40265-016-0559-2","article-title":"Dichlorphenamide: a review in primary periodic paralyses","volume":"76","author":"Greig","year":"2016","journal-title":"Drugs"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1212\/WNL.0000000000002416","article-title":"Randomized, placebo-controlled trials of dichlorphenamide in periodic paralysis","volume":"86","author":"Sansone","year":"2016","journal-title":"Neurology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s11940-020-00644-2","article-title":"Treatment updates for neuromuscular channelopathies","volume":"22","author":"Jitpimolmard","year":"2020","journal-title":"Curr Treat Options Neurol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"949068","DOI":"10.1155\/2014\/949068","article-title":"Evaluating the efficacy of primary treatment for graves' disease complicated by thyrotoxic periodic paralysis","volume":"2014","author":"Chang","year":"2014","journal-title":"Int J Endocrinol"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.1078784\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T04:44:49Z","timestamp":1673930689000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.1078784\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,17]]},"references-count":24,"alternative-id":["10.3389\/fneur.2022.1078784"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.1078784","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,17]]},"article-number":"1078784"}}